Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GABRG2 | SNV | Missense_Mutation | | c.1084G>T | p.Ala362Ser | p.A362S | P18507 | protein_coding | tolerated(0.51) | possibly_damaging(0.713) | TCGA-A8-A0A2-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
GABRG2 | SNV | Missense_Mutation | | c.288N>A | p.Met96Ile | p.M96I | P18507 | protein_coding | tolerated(1) | benign(0.01) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GABRG2 | SNV | Missense_Mutation | rs768061156 | c.1105G>T | p.Val369Phe | p.V369F | P18507 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EW-A1PE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
GABRG2 | SNV | Missense_Mutation | | c.1031N>A | p.Arg344Lys | p.R344K | P18507 | protein_coding | deleterious(0.01) | possibly_damaging(0.756) | TCGA-S3-A6ZG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
GABRG2 | SNV | Missense_Mutation | | c.1186T>A | p.Leu396Met | p.L396M | P18507 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A7CH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unspecific | | SD |
GABRG2 | SNV | Missense_Mutation | | c.187G>A | p.Glu63Lys | p.E63K | P18507 | protein_coding | tolerated(0.06) | possibly_damaging(0.516) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
GABRG2 | SNV | Missense_Mutation | | c.35N>T | p.Ser12Leu | p.S12L | P18507 | protein_coding | deleterious_low_confidence(0) | benign(0) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GABRG2 | SNV | Missense_Mutation | | c.8N>T | p.Ser3Leu | p.S3L | P18507 | protein_coding | deleterious_low_confidence(0.02) | benign(0.006) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GABRG2 | SNV | Missense_Mutation | | c.1121C>T | p.Ala374Val | p.A374V | P18507 | protein_coding | deleterious(0.02) | possibly_damaging(0.866) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GABRG2 | SNV | Missense_Mutation | | c.512G>T | p.Arg171Ile | p.R171I | P18507 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL1521 | ZALEPLON | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | | HALAZEPAM | HALAZEPAM | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | | GSK683699 | | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL1200602 | | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | | RO-229735 | CHEMBL2170369 | 21751815 |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL1200903 | SECOBARBITAL SODIUM | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL526 | PROPOFOL | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | | BROMAZEPAM | BROMAZEPAM | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | positive modulator | CHEMBL738 | THIOPENTAL SODIUM | |
2566 | GABRG2 | DRUGGABLE GENOME, ION CHANNEL | | RO-4882224 | CHEMBL1077391 | 19762240 |